PHAT
HealthcarePhathom Pharmaceuticals, Inc.
$15.83
+$0.12 (+0.76%)
Jan 5, 2026
Price History (1Y)
Analysis
Phathom Pharmaceuticals, Inc. is a biotechnology company operating in the healthcare sector with 427 employees. The company has a market capitalization of $1.13 billion and generates revenue of $147.19 million on a trailing twelve-month basis. The company's financial health is mixed. Phathom Pharmaceuticals reports an operating margin of -30.8% and a profit margin of -186.5%, indicating significant net losses. The company's return on assets is -42.5%, while its current ratio stands at 2.23, suggesting relatively manageable liquidity compared to its debt obligations. With cash reserves of $135.16 million and outstanding debt of $583.13 million, the company's balance sheet appears leveraged. Phathom Pharmaceuticals' valuation metrics are concerning, with a forward P/E ratio of -158.62 and an EV/EBITDA ratio of -7.36. The company's revenue growth has accelerated to 202.7% year-over-year, but its earnings growth is not publicly disclosed. Dividend information is not available for the company.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Visit website →Key Statistics
- Market Cap
- $1.13B
- P/E Ratio
- N/A
- 52-Week High
- $18.31
- 52-Week Low
- $2.21
- Avg Volume
- 988.80K
- Beta
- 0.49
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 427